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Introduction. The Chinese extract Rhizoma coptidis is well known for its anti-inﬂammatory, antioxidative, antiviral, and
antimicrobial activity. The exact mechanisms of action are not fully understood. Methods. We examined the eﬀect of the extract
and its main compound, berberine, on LPS-induced inﬂammatory activity in a murine macrophage cell line. RAW 264.7 cells
were stimulated with LPS and incubated with either Rhizoma coptidis extract or berberine. Activation of AP-1 and NFκBw a s
analyzed in nuclear extracts, secretion of MCP-1/CCL2 was measured in supernatants. Results. Incubation with Rhizoma coptidis
and berberine strongly inhibited LPS-induced monocyte chemoattractant protein (MCP)-1 production in RAW cells. Activation
of the transcription factors AP-1 and NFκB was inhibited by Rhizoma coptidis in a dose- and time-dependent fashion. Conclusions.
Rhizoma coptidis extract inhibits LPS-induced MCP-1/CCL2 production in vitro via an AP-1 and NFκB-dependent pathway. Anti-
inﬂammatory action of the extract is mediated mainly by its alkaloid compound berberine.
1.Introduction
Rhizoma coptidis is a commonly used herb in Chinese
medicine. It shows anti-inﬂammatory, anti-oxidative, anti-
viral, and anti-microbial activity and is therefore used
for a number of diﬀerent medical conditions, mainly for
dermatological disorders including acne, neurodermatitis
and skin ulcers. The main compound of Rhizoma coptidis,
the benzylisoquinoline alkaloid berberine, was also shown
to display beneﬁcial eﬀects on conditions associated with
hyperglycemia [1–4]a n dt ol o w e rs e r u mc h o l e s t e r o l[ 5].
The potent actions of Rhizoma coptidis and berberine have
been investigated in a number of diﬀerent cell lines, such
as keratinocytes [6], cancer cells [7–9], human hepatoma
cells [10], vascular smooth muscle cells [11, 12], and
HepG2 cells [13]. However there is only limited mechanistic
data on the eﬀects of Rhizoma coptidis and berberine and
they are mainly limited to in vitro studies. Few studies
have investigated Rhizoma coptidis or berberine in animal
models. Total alkaloids from Rhizoma coptidis proved to
be protective against H. pylori LPS-induced gastric lesions
in rats [14]. In another study, a combination of herbal
extracts, including components of Rhizoma coptidis showed
anti-inﬂammatory activities as potent as the eﬀects observed
with high doses of celecoxib or dexamethasone in acute and
chronic inﬂammation models [15].
Despite the well-described anti-inﬂammatory action,
there is little data on interactions of the total extract or2 Mediators of Inﬂammation
berberine on mononuclear cells. The transcription factor
activator protein 1 (AP-1) plays a critical role in inﬂamma-
tion and carcinogenesis. Nuclear factor-kappaB (NFκB) is
involved in the regulation of cytokine production. Monocyte
chemoattractant protein 1 (MCP-1/CCL2) is a cytokine that
attracts blood monocytes and tissue macrophages and is
therefore involved in chronic inﬂammatory disorders, for
example, atherosclerosis.
In the present paper, we examined the eﬀect of the
extract and its main compound, berberine, on LPS-induced
inﬂammatoryactivityinRAW264.7cells,amouseleukaemic
macrophage cell line.
2. Methods
2.1. Preparation of Rhizoma Coptidis Extract and Berberine.
Ten gramm Rhizoma coptidis were washed with distilled
water, dried and cut into small pieces. Herbs were diluted
in 100ml water and boiled for 2 hours. The solute was
percolated through ﬁlter paper (Whatman, pleated ﬁlter
grade 597 1/2, 4–7μm) and then sterilized by ﬁltration
through a 0.2μm pore ﬁlter (Minisart-plus, Sartorius).
Resulting Rhizoma coptidis extract was stored in aliquots at
−20
◦C until use.
Berberine, one of the main active alkaloids of Rhizoma
coptidis, was purchased from Sigma (Taufkirchen, Germany)
The substrate was diluted in methanol to generate a stock
solution with a ﬁnal concentration of 10−2 mol. For the
experiments, the stock solution was diluted with serum free
medium(ﬁnaltotalvolume4mL)togenerateconcentrations
of 10−3,1 0 −4,1 0 −5,a n d1 0 −6 mol for the cell culture
experiments.
2.2. Cell Culture. The murine macrophage cells (RAW 264.7;
ATCC, Manassas, VA) were grown in RPMI (PAA, Pasching,
Austria) and supplemented with 10% heat-inactivated FCS.
Cells were seeded at a density of 2.5 × 106 per 10cm
culture dish. After attachment and before start of the
experiments, cells were changed to serum-free medium
(RPMI). Rhizoma coptidis or berberine was added in various
dilutions for diﬀerent time points. LPS (Sigma, Taufkirchen,
Germany) was diluted in serum-free medium in a ﬁnal
concentration of 2μg/mL and added to the cells 30 minutes
prior end of the incubation period. To compare anti-
inﬂammatory activity, eﬀects of several statins (10−4 mol
rosuvastatin; 10−4 mol ﬂuvastatin) and angiotensin receptor
blockers (10−4 mol olmesartan, 10−4 mol telmisartan) were
also evaluated (exposure time 240min) on LPS-stimulated
RAW 264.7 cells.
2.3. Preparation of Nuclear Extracts. Nuclear extracts were
isolatedusingthemethodofHoppe-Seyleretal.[16].Brieﬂy,
cells were washed 3x with PBS and lysed directly on the
culture dish in 1.0mL cold RNA lysis buﬀer (0.6% NP40,
0.15M NaCl, 10mM Tris pH 7.9 and 1mM EDTA) and the
nuclear proteins were extracted into 50μlc o l de x t r a c t i o n
buﬀer containing 10mM Hepes pH 7.9, 0.1mM EGTA,
0.1mM EDTA, 1.5mM MgCl2, 420mM NaCl, 25% glyc-
erol and a proteinase inhibitor cocktail containing AEBSF,
pepstatin A, E-64, bestatin, leupeptin and aprotinin (Sigma,
Taufkirchen, Germany) and stored at −80
◦C. Protein was
measured using the Bradford protein dye reagent (Bio-Rad,
Munich, Germany).
2.4. Transcription Factor Activity. For electrophoretic mobil-
ity shift assays (EMSA), a double-stranded oligonucleotide
(Santa Cruz) representing the consensus-binding site for AP-
1a n dN F κB were radiolabeled with γ-32P-ATP using T-4
polynucleotide kinase (Promega, Madison, WI). The labeled
oligonucleotideswereincubatedwith5μgofnuclearproteins
and loaded on a 4% nondenaturating acrylamide gel for
separation from the unbound oligonucleotides according to
the manufacturer’s manual (Promega). To demonstrate the
speciﬁcity of the EMSA, cold competition was tested in each
individual assay. Gels were analyzed by phosphorimaging
(Cyclone, Packard Instruments, Meriden, CT).
2.5. Inﬂammatory Mediators in Supernatants. Supernatants
from LPS-stimulated cells, with and without incubation
with either Rhizoma coptidis, berberine (10−4 mol), statins
(10−6 mol rosuvastatin, 10−6 mol ﬂuvastatin), or angiotensin
receptor blockers (10−5 mol telmisartan, 10−5 mol olmesar-
tan) were obtained and stored at −80
◦C until use. MCP-
1/CCL2, interleukin-1 (IL-1)-beta, and interleukin-12 (IL-
12) concentrations were measured with a mouse Elisa
kit (R&D Systems, Wiesbaden, Germany) following the
manufacturer’s protocol.
Nitric oxide (NO) is a gaseous free radical with a short
half-life of a few seconds or less. Therefore, the levels of
the more stable NO metabolites, nitrite (NO2
−) and nitrate
(NO3
−), have been used in the indirect measurement of
NO in biological ﬂuids. Nitrate was converted to nitrite
using nitrate reductase. Total nitrite and endogenous nitrite
were measured in supernatants using a colorimetric assay
(R&D Systems, Wiesbaden, Germany). To obtain the nitrate
concentration, endogenous nitrite was subtracted from the
total nitrite value.
2.6. Statistical Analysis. Statistical analysis was performed
using the unpaired Students t-test. Data are presented as
mean ± S.E.M., and values of P<. 05 were considered
statistically signiﬁcant. All experiments were performed at
least three times and representative results are shown.
3. Results
3.1. Morphology. Morphology and total protein count of
adherent RAW 264.7 cells did not diﬀer between LPS-
stimulated control cells and LPS-stimulated cells, preincu-
bated with various dilutions of Rhizoma coptidis extract
(between1:2 and 1:20), evenafterexposure times ofup
to 360min (dilution 1:5), or with berberine in concentra-
tions of up to 10−3 mol. Representative cell morphology is
displayed on Figure 1.Mediators of Inﬂammation 3
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Figure 1: Morphology of RAW 264.7 cells cultured in standard medium (a), after stimulation with LPS (b), after LPS-stimulation and
exposure to either total extract of Rhizoma coptidis (dilution 1 : 5) (c), or to berberine (10−4 mol) (d). Activation with LPS resulted in
moderate reduction of total cell numbers and moderate altered cell morphology. No apparent morphologic changes were observed between
the diﬀerent LPS-stimulated cells.
LDH concentrations were slightly higher in supernatants
from LPS-stimulated cells (31.3 ± 0.6U/l, P<. 05) as
compared with control cells. No signiﬁcant diﬀerences were
found in supernatants from LPS-stimulated cells exposed
to Rhizoma coptidis (24.3 ± 14.6U/l), and from LPS-
stimulated cells exposed to berberine (30.3 ± 18.7U/l), as
compared to supernatants from control cells (17.6±6.7U/l);
(supernatants from the highest concentrations of Rhizoma
coptidis and berberine evaluated; data are mean from 3
independent experiments). No signiﬁcant diﬀerences were
observed between the diﬀerent LPS-stimulated cells.
3.2. AP-1 Activity. Incubation of LPS-stimulated RAW cells
with Rhizoma coptidis inhibited AP-1 activity in a concen-
tration (incubation time 240 minutes), (Figure 2(a))a n d
time dependent fashion (dilution 1:5), (Figure 2(b)). For
example, AP-1 activity in nuclear extracts of LPS-stimulated
RAW 264.7 cells was reduced by more than 90% after
preincubationfor360minwith1 : 5dilutedRhizoma coptidis
extract,ascomparedtonuclearextractsfromLPS-stimulated
controlcells.SigniﬁcantreductionofLPS-inducedactivation
of AP-1 was already observed as early as after 30min
of preincubation (dilution 1:5), (Figure 2(b)). Profound
reduction of AP-1 activity was still observed 48 hours
postexposure to Rhizoma coptidis (data not shown).
3.3. NFκ BA c t i v i t y .Signiﬁcant reduction of transcrip-
tion factor NFκ B activity required higher concentrations
(Figure 3(a)) and longer preincubation times (Figure 3(b))
with Rhizoma coptidis extract, as compared with eﬀects on
AP-1 activity. Statistical signiﬁcant reduction was observed
with dilutions of up to 1:5 (incubation time 240min),
(Figure 3(a))andafterincubationtimes of240minorlonger
(dilution 1:5), (Figure 3(b)). Surprisingly, low concentra-
tions of Rhizoma coptidis extract (1:20, incubation time
240min) caused a mild but signiﬁcant increase of NFκ B
activity (P<. 005), (Figure 3(a)). Profound downregulation
of NFκ B activity at higher concentrations (1:2 and 1:5)
persisted 48 hours after exposure to the total extract. Again,
exposure to low concentrations (1:20) of Rhizoma coptidis
resulted in enhanced NFκ B activity (data not shown).
3.4. Eﬀects of Berberine. Incubation with the main alkaloid
compound of Rhizoma coptidis, berberine, also signiﬁcantly
inhibited binding activity of AP-1 (Figure 4(a))a n dN F κ
B( Figure 4(b)), at concentrations of 10−4 mol or higher
(incubation time 240min). The pattern and magnitude
of the inhibitory eﬀects of berberine on transcription
factor activity suggests that it represents the main anti-
inﬂammatory compound of Rhizoma coptidis.
3.5. Comparison with other Anti-Inﬂammatory Agents. Incu-
bation with the main alkaloid compound of Rhizoma cop-
tidis, berberine, also signiﬁcantly inhibited binding activity
of AP-1 (Figure 4(a))a n dN F κ B( Figure 4(b)), at concen-
trations of 10−4 mol or higher (incubation time 240min).4 Mediators of Inﬂammation
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Figure 2: Binding activity of the transcripton factor AP-1 in nuclear extracts of LPS-stimulated RAW 264.7 cells. Eﬀects of total extract of
Rhizoma coptidis was evaluated with diﬀerent concentrations (incubation time 240min), (a) and exposure times (dilution 1:5), (b) and
was compared with transcription factor activation in LPS-stimulated control cells. Values represent results from at least three independent
experiments. AP-1: activated protein-1, Co: LPS-stimulated control cells, and CC: cold competition. ∗P<. 005, ∗∗P<. 001.
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Figure 3:Gel-shiftanalysisofthetranscriptonfactorNFκB.TreatmentwithRhizomacoptidisinhibitedbindingactivityinadose-dependent
(incubation time 240min), (a) and time-dependent (dilution 1 : 5), (b) fashion. NFκ B: nuclear factorκ B, Co: LPS-stimulated control cells,
and CC: cold competition. ∗P<. 005, ∗∗P<. 001.
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Figure 4: The main alkaloid compound of Rhizoma coptidis, berberine, inhibited binding activity of AP-1 (a) and NFκ B (b) in a
concentrationdependentfashion.InhibitorypotentialofberberinewasdirectlycomparedwiththetotalextractofRhizomacoptidis(dilution
1 : 5, incubation time 240min). LPS-stimulated cells were incubated for 240min. Berberine concentrations listed represent mol. AP-1:
activatedprotein-1,NFκB:nuclearfactorκB,Co:LPS-stimulatedcontrolcells,RC:Rhizomacoptidis,Be:berberine,andCC:coldcompetition.
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Figure 5: Direct comparison of cholesterol synthase inhibitors, angiotensin receptor blockers, total extract of Rhizoma coptidis (dilution
1 : 5), and berberine (dilution 10−4 mol) on transcription factor activity of AP-1 (a) and NFκ B (b). Exposure time of all substrates was
240min. AP-1: activated protein-1, NFκ B: nuclear factorκB ,C o :L P S - s t i m u l a t e dc o n t r o lc e l l s ,RC:Rhizoma coptidis, Be: berberine, Ros:
10−6 mol rosuvastatin, Flu: 10−6 mol ﬂuvastatin, Tel: 10−5 m o lt e l m i s a rt a n ,O l m :1 0 −5 mol olmesartan, and CC: cold competition. ∗P<. 005,
∗∗P<. 001.
The pattern and magnitude of the inhibitory eﬀects of
berberine ontranscription factoractivity suggeststhatitrep-
resents the main anti-inﬂammatory compound of Rhizoma
coptidis.
HMG-Co enzyme A reductase inhibitors (statins) as
well as ACE-inhibitors and angiotensin receptor blockers
(ARBs)areknownfortheirpotentanti-inﬂammatoryeﬀects.
Preincubation with the ARB olmesartan resulted in a small,
but signiﬁcant reduction of AP-1 activity in LPS-stimulated
RAW cells (P<. 005); however, the eﬀect was by far
less profound as compared with Rhizoma coptidis extract
(dilution 1 : 5) and with berberine (10−4 mol), (Figure 5(a)).
All other tested statins and ARBs failed to show signiﬁcant
eﬀects on AP-1 activity, (Figure 5(a)). No signiﬁcant eﬀects
onNFκBactivitywereobservedwithanyofthetestedstatins
and ARBs, (Figure 5(b)).
3.6. Secretion of MCP-1/CCL2, IL-1 beta, IL-12, and NO.
Secretion of monocyte chemoattractant protein-1 by LPS-
stimulated RAW 264.7 cells was also signiﬁcantly reduced
in a concentration- (Figure 6(a)) and time-dependent
(Figure 6(b))f a s h i o n ,a se v a l u a t e db yE L I S A so fs u p e r -
natants. Following the results of the Rhizoma coptidis assays,
higher concentrations of berberine potently inhibited MCP-
1/CCL2 secretion (Figure 6(c)). Again, preincubation of
stimulatedcellswithvariousstatinsandARBsdidnotinhibit
LPS-induced secretion of MCP-1/CCL2 by RAW cells (data
not shown). In contrast to the results of the transcription
factor essays, MCP-1/CCL2 secretion was signiﬁcantly inhib-
ited already after pretreatment with low concentrations of
Rhizoma coptidis or berberine (Figure 6(c)), suggesting that
inhibitory eﬀects on cytokine secretion might not exclusively
be mediated via AP-1 and NFκ B. MCP-1/CCL2 levels were
suppressed by Rhizoma coptidis (218pg/mL and 956pg/mL)
but not by berberine (2125pg/mL and 2269pg/mL) as
compared with LPS-stimulated control cells (2335pg/mL
and 2355pg/mL), 24 hours, respectively, 48 hours post
exposure.
Surprisingly, concentration of interleukin-1 beta and
interleukin-12, two inﬂammatory mediators, was below
detectable levels in all supernatants tested, using standard
ELISA kits (R&D Systems, Wiesbaden, Germany) (data not
shown). It is possible that cell numbers in the present
setting and therefore cytokine secretion was too low to
reach detectable levels of IL-1 beta and IL-12. Produc-
tion of total nitrite (NO2
−) was signiﬁcantly inhibited by
Rhizoma coptidis (245 ± 25.7pg/mL, dilution 1:2, P<
.001; 329 ± 28.8pg/mL, dilution 1:5, P<. 001; 407 ±
27.6pg/mL, dilution 1:10, P<. 001;512 ± 44.7pg/mL,
dilution 1:20, P<. 05), as compared to LPS-stimulated
RAWcells(635±16.9pg/mL).Incubationwithberberineina
concentrationof10−4 moldidnotinhibitproductionoftotal
nitrite(651±32.5pg/mL,n.s.).Endogenousnitritewasbelow
detectable levels in all supernatants evaluated; therefore,
nitrate concentration equals total nitrite concentration in
our assays.
4. Discussion
The eﬀect of Rhizoma coptidis and its possible mechanisms
have been evaluated in a number of diﬀerent cell lines.
Since Rhizoma coptidis is well established in the treatment of
commondermatologicaldisorders,Enketal.investigatedthe
eﬀectoftheextractonTNF-αinducedNFκBtranslocationin
human keratinocytes [6]. Translocation of NFκB into the cell
nucleus after stimulation with TNF-α could be inhibited in
a dose-dependent fashion by the total extract, but not by its
main alkaloid compound berberine. Authors conclude that
berberine exerts its anti-inﬂammatory eﬀects by inhibiting
signal transduction pathways other than the NFκBd e p e n -
dentpathway.Inthepresentstudy,MCP-1/CCL2secretionof
RAWcellswassigniﬁcantlyinhibitedalreadyafterincubation
with concentrations of Rhizoma coptidis or berberine that
did not signiﬁcantly inhibit transcription factor activation,
suggestingthatinhibitoryeﬀectsoncytokinesecretionmight
not exclusively be mediated via AP-1 and NFκB. The pattern6 Mediators of Inﬂammation
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Figure 6: Secrection of MCP-1/CCL2 was evaluated with ELISAs of supernatants. Supernatants were collected after preincubation with
diﬀerent concentrations (a) and exposure times (b) of Rhizoma coptidis. Berberine also inhibited MCP-1/CCL2 secretion in a concentration-
dependent fashion (c). Berberine concentrations listed represent mol. LPS: lipopolysaccharide, RC:Rhizoma coptidis, Be: berberine, MCP-
1/CCL2: monocyte chemoattractant protein-1. ∗P<. 005, ∗∗P<. 001. AP-1: activated protein-1, Co: LPS-stimulated control cells, and CC:
cold competition. †P<. 05, ∗P<. 005, ∗∗P<. 001.
and magnitude of the inhibitory eﬀects of berberine on
transcription factor activity in our experiments supports the
hypothesis, that it represents the main anti-inﬂammatory
compound of Rhizoma coptidis.
Berberine displays a number of potential beneﬁcial
eﬀects in cancer cells and might therefore also exerts anti-
cancer properties [8, 9, 17]. The alkaloid induces production
of reactive oxygen species (ROS) and downregulation of
several matrix metalloproteinases (MMP-1) both on mRNA
as well as on protein level [7]. Another study showed
that berberine suppresses invasion of cancer cells through
diﬀerentsignallingpathwaysresultingininhibitionofMMP-
2[ 8]a n dM M P - 9[ 8, 9]. MMPs not only play a role in
carcinogenesis; matrix-degrading proteases can destabilize
atherosclerotic lesions and therefore also play an important
role in advanced cardiovascular disease. Oxidative modiﬁ-
cation of low-density lipoprotein (LDL) is a crucial step in
rather earlier stages of atherogenesis. Again, in a study by
Hsieh et al., berberine was shown to inhibit generation of
ROSbutalsotoreduceLDLoxidationandtopreventoxLDL-
induced cellular dysfunction in endothelial cells [18].
Our study is one of few reports of the anti-inﬂammatory
activity of Rhizoma coptidis in a macrophage cell line [19–
22]. This is of particular interest, since macrophages play a
crucialroleinvariousstagesofatherosclerosis,anditsclinical
sequelae coronary artery disease and stroke. Atherosclerotic
lesions develop as a result of a sustained immune response
to chronic inﬂammatory processes in the vessel wall, often
caused by endothelial injury [23]. Monocytes play a crucial
role in initiating and maintaining vascular inﬂammation.
Monocytes convert to macrophages, consume oxidized
lipids,andsubsequentlyformcharacteristicfoamcells.Foam
cells then again secrete proinﬂammatory cytokines which
perpetuate the inﬂammatory response, leading eventually
to fatty streak formation. After fatty streaks are estab-
lished, macrophages constitutively secrete proatherosclerotic
mediators, for example, inﬂammatory proteins, MMPs,
adhesion molecules, and chemokines such as MCP-1/CCL2
[24]. MCP-1/CCL2 further attracts circulating monocytes
and tissue macrophages and therefore contributes to the
sustained inﬂammation within the vessel wall.
Our observations, that Rhizoma coptidis exerts its
anti-inﬂammatory mechanisms, at least in part, through
inhibitory eﬀects on MCP-1/CCL2 production, is supported
by studies of Ko et al.. Zoagumhwan water extract, a Korean
herbal remedy as well as berberine inhibited angiotensin II-
induced MCP-1/CCL2 expression and monocyte adhesion
to human umbilical vein endothelial cells [25]. In the
same line, berberine was shown to inhibit the expression
of TNFalpha, IL-6, and MCP-1/CCL2 in acLDL-stimulated
macrophages [26]. In contrast to our observations, Li et al.
report of potential proatherosclerotic eﬀects of berberine.
The compound induced foam cell formation in RAW 264.7
cellsaswellasinmouseandhumanprimarymacrophagesbyMediators of Inﬂammation 7
upregulating scavenger receptor A expression [27]. Authors
conclude that promotion of foam cell formation, a hallmark
in early atherogenesis, could therefore counter-balance the
beneﬁcial eﬀect of berberine on serum cholesterol levels,
which is believed to be mediated by inducing LDL receptors
in hepatic cells [5, 28]. We strongly believe that the well-
described potent anti-inﬂammatory actions of berberine by
far outweigh its potential eﬀects on stimulating uptake of
modiﬁed LDL in vitro. In the present paper, we focused on
anti-inﬂammatorymechanismsofbothRhizomacoptidisand
berberine on a transcriptional and post-transcriptional level.
Assessment of foam cell formation or even induction of early
atherosclerotic lesions was not subject of the present study.
Few studies investigated the eﬀects of Rhizoma coptidis
or berberine in in vivo models. The total extract was
shown to be protective against H. pylori LPS-induced gastric
mucosal inﬂammation. The concerned mechanisms seem
to be related to its inhibition on epithelial cell apoptosis,
upregulating cNOS, and reducing serum concentrations of
TNF-alpha [14]. The observation that Rhizoma coptidis
acts through TNF-alpha inhibition is consistent with results
of our study, since NFκB and AP-1 are the two main
downstream eﬀectors of TNF-alpha. Berberine was also
shown to display beneﬁcial eﬀect on conditions associated
with hyperglycemia [1–4]. The alkaloid prevents fructose-
induced insulin resistance in rats by promoting hepatocyte
nuclear factor-4alpha [1]. Berberine also increases insulin
expression and antioxidant enzyme activity, promotes beta
cellregeneration,anddecreaseslipidperoxidationindiabetic
rats [4].
Park et al. used a croton oil-induced ear edema model
and an acetic acid-induced capillary permeability test to
evaluate the eﬀects of a combined herbal preparation
(RAH13), of which Coptis chinensis is a main compound.
Models of chronic inﬂammation were also tested, using the
cotton pellet test and a delayed-type hypersensitivity test.
Oral administration of RAH13 showed anti-inﬂammatory
activity in vivo as potent as with high doses of celecoxib or
dexamethasone [15].
Several substances and drugs, mainly statins and
ACE-inhibitors or ARBs are thought to improve out-
come in cardiovascular patients, at least in part, via
their anti-inﬂammatory action. In the present study, anti-
inﬂammatory activity of Rhizoma coptidis exceeded those
observed with various statins and ARBs. With its potent
inhibitory eﬀects on transcription factor activity and MCP-
1/CCL2 secretion in vitro, together with its well described
lipid lowering and hypoglycemic properties, Rhizoma cop-
tidis might be of potential beneﬁt for patients with
atherosclerotic disease. Further in vivo and clinical studies
seem to be warranted to elucidate the potential role of
Rhizoma coptidis in the prevention or treatment of patients
with metabolic syndrome or cardiovascular disease.
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